ALEMBIC
|
ALEMBIC Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 12.10 | 10.46 | 7.42 | 8.65 | 13.35 |
| CEPS(Rs) | 6.04 | 3.92 | 3.40 | 3.55 | 0.69 |
| DPS(Rs) | 2.40 | 2.40 | 2.20 | 1.80 | 0.20 |
| Book NAV/Share(Rs) | 91.07 | 85.11 | 80.93 | 97.23 | 89.45 |
| Tax Rate(%) | 7.03 | 9.56 | 7.12 | 11.92 | 18.78 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 42.23 | 36.11 | 31.70 | 17.81 | 14.18 |
| EBIT Margin(%) | 71.20 | 65.91 | 68.58 | 125.61 | 23.67 |
| Pre Tax Margin(%) | 70.08 | 65.20 | 68.21 | 125.11 | 23.18 |
| PAT Margin (%) | 65.16 | 58.97 | 63.36 | 110.20 | 18.83 |
| Cash Profit Margin (%) | 69.95 | 63.95 | 68.64 | 116.42 | 24.19 |
| Performance Ratios | |||||
| ROA(%) | 5.96 | 4.09 | 3.33 | 3.42 | 0.71 |
| ROE(%) | 6.39 | 4.36 | 3.52 | 3.60 | 0.75 |
| ROCE(%) | 6.95 | 4.86 | 3.82 | 4.10 | 0.94 |
| Asset Turnover(x) | 0.09 | 0.07 | 0.05 | 0.03 | 0.04 |
| Sales/Fixed Asset(x) | 1.44 | 1.04 | 0.84 | 0.52 | 0.50 |
| Working Capital/Sales(x) | 2.35 | 3.35 | 1.44 | 1.04 | 1.72 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.69 | 0.96 | 1.19 | 1.92 | 2.01 |
| Receivable days | 40.90 | 50.08 | 55.47 | 67.74 | 56.58 |
| Inventory Days | 157.91 | 210.00 | 251.69 | 329.34 | 222.67 |
| Payable days | 156.42 | 180.44 | 162.67 | 299.17 | 252.73 |
| Valuation Parameters | |||||
| PER(x) | 8.14 | 8.00 | 7.99 | 8.37 | 7.70 |
| PCE(x) | 16.30 | 21.33 | 17.43 | 20.40 | 148.53 |
| Price/Book(x) | 1.08 | 0.98 | 0.73 | 0.74 | 1.15 |
| Yield(%) | 2.44 | 2.87 | 3.71 | 2.49 | 0.19 |
| EV/Net Sales(x) | 11.44 | 13.68 | 11.95 | 23.73 | 35.84 |
| EV/Core EBITDA(x) | 15.06 | 19.30 | 14.54 | 18.00 | 123.44 |
| EV/EBIT(x) | 16.07 | 20.76 | 17.43 | 18.89 | 151.39 |
| EV/CE(x) | 1.08 | 0.98 | 0.73 | 0.71 | 1.09 |
| M Cap / Sales | 11.40 | 13.64 | 11.97 | 23.75 | 35.92 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 40.89 | 23.77 | 62.68 | 6.39 | -0.55 |
| Core EBITDA Growth(%) | 51.03 | 6.73 | 1.44 | 383.10 | -77.92 |
| EBIT Growth(%) | 52.20 | 18.94 | -11.18 | 464.53 | -81.38 |
| PAT Growth(%) | 55.67 | 15.19 | -6.47 | 522.73 | -85.12 |
| EPS Growth(%) | 15.66 | 40.90 | -14.15 | -35.23 | 4.17 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | - | - | - | - |
| Current Ratio(x) | 1.74 | 1.49 | 1.99 | 2.12 | 1.72 |
| Quick Ratio(x) | 0.96 | 0.53 | 1.00 | 0.83 | 0.80 |
| Interest Cover(x) | 63.93 | 93.63 | 187.54 | 252.50 | 48.08 |
| Total Debt/Mcap(x) | 0.01 | - | - | - | - |
Compare Financial Ratios of peers of ALEMBIC
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ALEMBIC | ₹2,381.8 Cr | 2.4% | -7.3% | -23.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹381,326.0 Cr | -0.2% | -6.3% | -8.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹160,299.0 Cr | 3.3% | -3.4% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹132,821.0 Cr | -0.7% | 3.8% | 26.3% | Stock Analytics | |
| CIPLA | ₹106,655.0 Cr | -3% | -11.8% | -8.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,861.0 Cr | 6% | -3.5% | -4.3% | Stock Analytics | |
ALEMBIC Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALEMBIC | 2.4% |
-7.3% |
-23.8% |
| SENSEX | 0.8% |
-2.9% |
8.1% |
You may also like the below Video Courses
